Researchers published a Nature Communications paper describing a sonically activated polypeptide‑based 'sono‑adjuvant' that, when triggered by ultrasound, modulates innate immunity and enhanced cancer vaccine responses in preclinical models. The two‑component system enables spatial and temporal control of immune stimulation, reportedly increasing antigen presentation and T‑cell priming without systemic toxicity. The team demonstrated tumor control in murine models when ultrasound‑triggered adjuvanting was combined with antigen delivery, and they mapped innate immune activation pathways consistent with improved adaptive responses. Sono‑adjuvants aim to localize immune activation to the tumor microenvironment or vaccine site, reducing off‑target inflammation. Translational steps will require demonstration of manufacturing scalability, ultrasound device compatibility, and safety in large‑animal models before human trials; developers and device partners will need regulatory alignment for a combined drug‑device therapeutic approach.